Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates
about
Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromeImpact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplantPrimary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.Psychosocial factors and hematopoietic stem cell transplantation: potential biobehavioral pathwaysHigh CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unDonor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.Bone marrow produces sufficient alloreactive natural killer (NK) cells in vivo to cure mice from subcutaneously and intravascularly injected 4T1 breast cancer.Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors.Optimizing Stem Cells Mobilization Strategies to Ameliorate Patient Outcomes: A Review of Guide- lines and Recommendations.Higher dose of CD34+ peripheral blood stem cells is associated with better survival after haploidentical stem cell transplantation in pediatric patients.Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation.CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.Donor body mass index is an important factor that affects peripheral blood progenitor cell yield in healthy donors after mobilization with granulocyte-colony-stimulating factor.Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease.Impact of CD34+ cell dose in children who receive unrelated PBSCT with in vivo T-cell depletion for hematologic malignancies.A higher number of infused CD34(+) cells has a positive impact on the clinical outcome after related PBSC transplantation.G-CSF downregulates natural killer cell-mediated cytotoxicity in donors for hematopoietic SCT.Equivalent outcomes using reduced intensity or conventional myeloablative conditioning transplantation for patients aged 35 years and over with AML
P2860
Q30371042-7B60388A-14C6-41EF-9F4F-55328E1502FCQ34169235-E844AE0E-A463-4F0F-AFBF-402BC1A271A8Q35925091-E399DFED-F850-4796-982D-C710EEB50539Q37266089-6E277A46-07B0-4136-B9D5-56CCD5F9E42BQ37317226-FE3BF8ED-380E-4CEF-95FA-28B00A0FC772Q37372806-CAC2748C-97D9-44A8-9A5C-95D81DC86E4EQ37590606-7888E8F2-CCFA-428D-8111-3C428088FABDQ37618917-83B4274B-2123-411D-AC59-25EACC84C1EFQ37682128-C6AC728C-1CA5-4CE8-B0C2-473D6B692A75Q39152763-834539F6-034F-4442-A180-4DE09BF513F6Q39186228-ECC5CDAB-8010-4D63-93C6-0174B45D73ABQ43140217-8747555D-2CEB-48E4-947A-C12D8DE32A1EQ45888274-6F7C973E-DBD3-4B74-894B-8A73319ACF5DQ45928979-7D99C5B2-40CF-4871-A7FF-F9A721B91E7CQ46208758-21A7F26D-E18E-4391-A30D-8043AD83B9CCQ47983957-B5666A64-BE1A-48AF-B182-5A668F16AAA1Q50986967-B8D7BEA0-CEBD-4F1F-B426-2EAE643F6F1AQ53015676-A9216D37-B541-4A72-BFB0-710C0E31FA05Q53053280-642E9976-A27A-49E3-849A-ED6AAB7B0213Q54609253-FA353AEE-9697-4CF9-B25C-086E86CBBCCBQ58814184-77AC6A6A-DECA-483D-AD59-ADBCD89FEEB4
P2860
Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Impact of graft cell dose on t ...... d with decreased relapse rates
@ast
Impact of graft cell dose on t ...... d with decreased relapse rates
@en
type
label
Impact of graft cell dose on t ...... d with decreased relapse rates
@ast
Impact of graft cell dose on t ...... d with decreased relapse rates
@en
prefLabel
Impact of graft cell dose on t ...... d with decreased relapse rates
@ast
Impact of graft cell dose on t ...... d with decreased relapse rates
@en
P2093
P2860
P1476
Impact of graft cell dose on t ...... d with decreased relapse rates
@en
P2093
Anthony Stein
Chatchada Karanas
David D Smith
David Senitzer
Jeffrey Schriber
Joel Y Sun
Joseph Rosenthal
Joycelynne Palmer
Nademanee Auayporn
P2860
P304
P356
10.1016/J.BBMT.2008.02.005
P577
2008-04-01T00:00:00Z